Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for mechanically ventilated ICU patients with COVID-19
IRCT20211017052786N1Phase 3Completed
- Sponsor
- Qom University of Medical Sciences
- Start
- Jan 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of colchicine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Qom University of Medical Sciences. Primary endpoints: Mortality rate and Duration of hospitalization. Started Jan 2022; status: completed.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20211017052786N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211017052786N1.